The Pediatric infectious disease journal
-
Pediatr. Infect. Dis. J. · Jun 2010
Randomized Controlled TrialSafety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
A booster dose of pneumococcal conjugate vaccine may be administered at the same age as measles-mumps-rubella-varicella (MMRV) vaccination. This study examined the safety, reactogenicity, and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with MMRV vaccine. ⋯ PHiD-CV and MMRV vaccine can be coadministered without compromising the safety and immunogenicity profiles of either vaccine.
-
Pediatr. Infect. Dis. J. · Jun 2010
Case ReportsAdolescent with neuropsychiatric symptoms associated with novel influenza A (H1N1) virus infection.
Neurologic complications have been described previously in association with seasonal influenza A or B viruses, but the frequency with which these occur with novel influenza A (H1N1) virus infection is unknown. We describe a case of an adolescent with a bizarre neuropsychiatric picture associated with novel influenza A (H1N1) virus infection.